Hamish J Allen

US Patent:

20020099169, Jul 25, 2002

Filed:

Aug 13, 1999

Appl. No.:

09/374579

Inventors:

HAMISH JOHN ALLEN - BOYLSTON MA, US
RICHARD WOODWARD DIXON - NORTH GRAFTON MA, US
JOANNE SARA KAMENS - NEWTON CENTRE MA, US
DINELI WICKRAMASINGHE - NEWTON MA, US
YAJUN XU - WESTBOROUGH MA, US
MONICA POLIDORO BELICH - LONDON, GB
LELAND HERRIES JOHNSTON - LONDON, GB
STEVEN CHARLES LEY - HIGH BARNET, GB
ANDRES SALMERON - LONDON, GB

Assignee:

BASF AKTIENGESELLCHAFT

International Classification:

A01N037/18
A61K038/00
G01N033/53
A61K039/395
C07K005/00
C07K007/00
C07K016/00
C07K017/00
C07K001/00
C07K014/00

US Classification:

530/324000, 435/007100, 530/350000, 530/387100, 514/002000, 424/130100

Abstract:

It is shown that TPL-2 is responsible for phosphorylation of p105 and its resultant proteolysis, which leads to p50 Rel translocation to the nucleus. Accordingly, the invention provides TPL-2 as a specific regulator of the activation of NF B, and thus as a modulator of inflammatory responses in which p105 is involved, and as a target for the development of compounds capable of influencing NF B activation.

US Patent:

20020156094, Oct 24, 2002

Filed:

Sep 25, 2001

Appl. No.:

09/964114

Inventors:

Hans Albrecht - Gorxheimertal, DE
Hamish Allen - Boylston MA, US
Kenneth Brady - Worcester MA, US
William Harter - Chelsea MI, US
Catherine Kostlan - Saline MI, US
Bruce Roth - Plymouth MI, US
Nigel Walker - Dossenheim, DE

Assignee:

Warner-Lambert Company

International Classification:

C07D217/22
C07C311/30
A61K031/47
A61K031/18

US Classification:

514/307000, 514/601000, 546/141000, 564/082000, 564/080000

Abstract:

The present invention relates to compounds that are inhibitors of interleukin-1 converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1 converting enzyme.

US Patent:

20030219427, Nov 27, 2003

Filed:

Feb 26, 2003

Appl. No.:

10/374414

Inventors:

Hamish Allen - Boylston MA, US
Richard Dixon - Jefferson MA, US
Joanne Kamens - Newton Centre MA, US
Dineli Wickramasinghe - San Francisco CA, US
Yajun Xu - Westborough MA, US
Nancy Bump - Lowell MA, US
Andres Salmeron - Westminster MA, US
Monica Belich - London, GB
Leland Johnston - London, GB
Steven Ley - Hertfordshire, GB
Steven Gamblin - Hertfordshire, GB
Stephen Smerdon - London, GB
Soeren Beinke - Wienhausen, DE
Juergen Deka - Lausanne, CH

International Classification:

A61K038/52

US Classification:

424/094500

Abstract:

It is shown that TPL-2 is responsible for phosphorylation of p105 and its resultant proteolysis, which leads to p50 Rel translocation to the nucleus. Accordingly, the invention provides TPL-2 as a specific regulator of the activation of NF B, and thus as a modulator of inflammatory responses in which p1O5 is involved, and as a target for the development of compounds capable of influencing NF B activation.

US Patent:

20060074102, Apr 6, 2006

Filed:

May 13, 2005

Appl. No.:

11/129624

Inventors:

Kevin Cusack - Holden MA, US
Thomas Gordon - Medway MA, US
Claude Barberis - Santeny, FR
Hamish Allen - Boylston MA, US
Agniezka Bischoff - Westborough MA, US
Anna Ericsson - Shrewsbury MA, US
Michael Friedman - Newton MA, US
Dawn George - Charlton MA, US
Gregory Roth - Woodstock CT, US
Robert Talanian - Harvard MA, US
Christine Thomas - Northborough MA, US
Grier Wallace - Sterling MA, US
Neil Wishart - Jefferson MA, US
Zhengtian Yu - Shrewsbury MA, US

International Classification:

A61K 31/4743
C07D 498/02

US Classification:

514301000, 546114000

Abstract:

A compound or pharmaceutically acceptable salts thereof of Formula (I) wherein the substituents are as defined herein, which are useful as kinase inhibitors.

US Patent:

20090311253, Dec 17, 2009

Filed:

Jun 3, 2009

Appl. No.:

12/477711

Inventors:

Tariq Ghayur - Holliston MA, US
Peter C. Isakson - Southborough MA, US
Lisa M. Olson - Hopkinton MA, US
Chengbin Wu - Shrewsbury MA, US
Margaret Hugunin - North Grafton MA, US
Rajesh V. Kamath - Shrewsbury MA, US
Carolyn A. Cuff - Grafton MA, US
Hamish J. Allen - Boylston MA, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 39/395
C07K 16/00
C07H 21/04
C12N 15/63
C12N 1/21
C12N 1/10
C12N 5/10
C12N 1/15
C12P 21/06

US Classification:

4241331, 5303871, 536 2353, 4353201, 43525233, 4352581, 435325, 435419, 43525411, 435348, 435349, 435358, 435365, 43525421, 435 696, 4241301

Abstract:

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

US Patent:

60839813, Jul 4, 2000

Filed:

Apr 9, 1999

Appl. No.:

9/284425

Inventors:

Hamish John Allen - Boylston MA
Kenneth Dale Brady - Worcester MA
William Glen Harter - Chelsea MI
Elizabeth Ann Lunney - Ann Arbor MI
Mark Stephen Plummer - Dexter MI
Tomi Sawyer - Southborough MA
Aurash Shahripour - Ann Arbor MI
Nigel Walker - Dossenheim, DE

Assignee:

Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 31341
C07D30740

US Classification:

514471

Abstract:

The present invention relates to compounds that are inhibitors of interleukin-1. beta. converting enzyme that have the Formula I, II, or III. ##STR1## This invention also relates to a method of treatment of stroke, inflammatory diseases, septic shock reperfusion injury, Alzheimer's disease, and shigellosis, and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1. beta. converting enzyme.

US Patent:

63164159, Nov 13, 2001

Filed:

Apr 9, 1999

Appl. No.:

9/284422

Inventors:

Hans P. Albrecht - Gorxheimertal, DE
Hamish John Allen - Boylston MA
Kenneth Dale Brady - Worcester MA
William Glen Harter - Chelsea MI
Catherine Rose Kostlan - Saline MI
Bruce David Roth - Plymouth MI
Nigel Walker - Dossenheim, DE

Assignee:

BASF Aktiengesellschaft - Ludwigshafen
Warner-Lambert Company - Morris Plains NJ

International Classification:

A61K 3118
A61K 3807

US Classification:

514 18

Abstract:

The present invention relates to compounds that are inhibitors of interleukin-1. beta. converting enzyme that have the Formula (I). This invention also relates to a method of treatment of stroke, reperfusion injury, Alzheimer's disease, shigellosis, inflammatory diseases, and septic shock and to a pharmaceutically acceptable composition that contains a compound that is an inhibitor of interleukin-1. beta. converting enzyme. ##STR1##.

US Patent:

59325496, Aug 3, 1999

Filed:

Apr 27, 1998

Appl. No.:

9/067053

Inventors:

Hamish John Allen - Shrewsbury MA
Subhashis Banerjee - Shrewsbury MA
Kenneth Dale Brady - Worcester MA
John Cooke Hodges - Ann Arbor MI
Catherine Rose Kostlan - Saline MI
Robert Vincent Talanian - Harvard MA

Assignee:

Warner-Lambert Company - Morris Plains NJ
BASF Aktiengesellschaft - Ludwigshafen

International Classification:

A61K 3805
A61K 3806
A61K 3809

US Classification:

514 18

Abstract:

The present invention relates to N-substituted derivatives of glutamic acid of pharmaceutical interest, to pharmaceutical compositions which include compounds of the invention and pharmaceutically acceptable carriers, to methods of their preparation, and to their use in purification of interleukin-1. beta. converting enzyme (ICE).